Database Update: Pharmaceutical Drug Import to Russia (October 2018)
Between January and October 2018, Russia imported 427.1 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 1.5% higher than that of the same period of 2017, and 87.9 bln RUB worth of in-bulk pharmaceuticals, which is in monetary terms 12.5% higher than that of the same period of 2017. In total, the dynamics in monetary terms are +3.2%.
In physical terms, Russia imported 1.5 bln units of ready-made pharmaceuticals, or 27.9 bln minimum dosage units (MDU.) The dynamics are -7.6% and -5.8%, respectively. The dynamics of the in-bulk import are +0.8% (3.5 bln MDU. The total import amounts to 31.5 bln units, with the dynamics being -5.1%.
In October 2018, Russia imported 50.1 bln RUB worth of ready-made pharmaceuticals, which is in monetary terms 4.4% higher than that of October 2017, and 6.7 bln RUB worth of in-bulk drugs, which is in monetary terms 16.2% lower than that of October 2017.
Among the top 20 companies with the biggest ready-made pharmaceutical drug import in monetary terms, MSD and Takeda have the highest dynamics. The dynamics of MSD are nearly +28%, with the import of follicle stimulating Purigon having increased by 89 times. The dynamics of Takeda are +25%. Its Alunbrig, used for lung cancer treatment, has not yet been registered in Russia and is imported only for certain patients for health reasons.
As for in-bulk importers, Merck Group and Concor have the biggest dynamics in monetary terms, with a 4.1 and 29 times increase, respectively. Amgen has also good dynamics (+300%), the import of its Vectibix, packaged by Russian Dobrolek, has increased by 5.6 times.
Read more about pharmaceutical drug import to Russia (September results) here: http://rncph.com/news/13_11_2018
Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – October 2018)